Get notified when IOVA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Immediate Dilution In Net Tangible Book Value of Approximately $1.04 Per Share (new) — New investors pay $2.60 per share but receive only $1.56 in net tangible book value per share, a 40% immediate dilution.
Iovance Biotherapeutics launches up to $350M at-the-market offering at $2.60/share
Filed August 22, 2025 · ~1 min read
Key Changes
-
high
Iovance is selling up to $350.0 million of common stock in an at-the-market offering, with shares priced at $2.60 based on the August 19, 2025 close.
The Offering verify on EDGAR → -
high
The offering is primary; all proceeds go to Iovance, not selling stockholders.
The Offering verify on EDGAR → -
high
Net proceeds are earmarked for the commercial launch of Amtagvi, clinical trials IOV-LUN-202 and TILVANCE-301, other pipeline development, and general corporate purposes.
Use of Proceeds verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (SAR 10-Q) is open in full — no account needed.
Partner
Trade IOVA commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 3, 2026 · How we verify